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Background: The purpose of this study is to systematically review the effectiveness of various drugs and 
therapies by assessing already conducted studies on COVID-19 patients. 
Methods: The eligibility criterion for this systematic review was to include the observational and experimental 
studies including case reports; conducted on the possible treatments of COVID-19. Only those studies were 
included that were written in the English language either published or unpublished from December 2019 to April 
10, 2020. Quality of articles was assessed and flawed studies were excluded based on incomplete outcome data. 
Treatment strategies experimented on animals or those assessed through artificial intelligence were also excluded. 
The databases searched were PubMed, Google Scholar, Cochrane Library, and bioRxiv. The last date to search the 
databases was April 10, 2020. 
Results: We selected 25 articles which include 12 case studies, 10 retrospective studies, one randomized 
controlled trial, one non-randomized Controlled trial, and one prospective observational study. 
Hydroxychloroquine proved to be effective in all three studies under consideration especially when it was used 
in a combination with azithromycin. Antivirals showed significant results in eleven out of sixteen studies. The 
remaining five studies showed antiviral therapy to be ineffective. Lopinavir/ritonavir did not show satisfactory 
results in most of the COVID-19 patients. Both of the studies regarding convalescent plasma therapy showed 
significant improvement in patients undergoing treatment. Two studies regarding treatment with 
immunoglobulins also showed good results. A study on the use of Mesenchymal stem cell transplant for 
treatment of COVID-19 patients also proved to be effective. Likewise, a study on the use of Traditional Chinese 
Medicine along with Western Medicine also showed good results. In patients of organ transplant, withdrawal of 
immunosuppressive drugs, and the use of methylprednisolone along with antivirals had shown significantly 
good results. Among all these therapeutic approaches we found convalescent plasma therapy to be most effective.  
Conclusion: So far, a small number of studies have been conducted on the treatment of COVID-19 patients and 
most of them were conducted on the Chinese population. More randomized controlled trials are needed to 
evaluate the effectiveness of different treatment strategies at a broader level. 
Keywords: COVID-19 treatment, SARS-COV-2, convalescent plasma therapy, Lopinavir/ritonavir, 
Hydroxychloroquine, and azithromycin, Remdesivir, COVID-19 serum therapy. 
 




In December 2019, a virus named ‘’Severe acute 
respiratory syndrome corona virus-2’’ (SARS-COV-2 
or COVID-19) infected people in China causing fever, 
dry cough, shortness of breath and pneumonia.1 Virus 
can be transmitted from one human to another.2 Now 
this mass killer infection is a pandemic around the 
world. This virus (COVID-19) has infected 1,684,833 
people, among them 375,499 people have recovered 
and 102,136 people have died till April 10, 2020. Many 
studies have been conducted around the world to 
devise an effective treatment for COVID-19. 
Investigational drugs anti-virals, antimalarials, anti-
inflammatory, Traditional Chinese Medicine, plasma 
technique, immunotherapies, and investigational 
vaccines are all the strategies applied for the 
management and treatment of COVID-19 around the 
globe. Our study systematically reviews the studies on 
the previously mentioned drugs and techniques and 
compares the effectiveness of different treatment 
strategies for COVID-19 in humans. The case reports 
describing the treatment strategies of patients having 





The eligibility criterion for this systematic review was 
to include the observational and experimental studies 
including case reports conducted on the possible 
treatments of COVID-19. Only those studies were 
included that were written in the English language 
either published or unpublished from December 2019 
to April 10, 2020. The databases searched were 
PubMed, Google Scholar, Cochrane Library, and 
bioRxiv. The last date to search the databases was 
April 10, 2020. The search terms used were COVID-19 
treatment, hydroxychloroquine, and azithromycin for 
COVID-19 treatment, Anti-malarial for COVID-19 
treatment, Antivirals for COVID-19 treatment, 
Serotherapy for COVID-19. Three reviewers 
individually searched the databases. At first step, 
reviewers selected the studies by reading the titles and 
abstracts, and those studies were selected which were 
related to the treatment of COVID-19. At the second 
step, three reviewers together removed the duplicates 
and rechecked the studies by consulting the full texts 
if needed and removed the articles which were not 
eligible. In the third step, the quality of articles was 
assessed and flawed studies were excluded based on 
incomplete outcome data after full-text review. 
Treatment strategies experimented on animals or 
those assessed through artificial intelligence were 
excluded. Studies having full-text articles in languages 
other than English were also excluded. Data extraction 
was done by three authors individually and rechecked 
by one author. The variables used for data extraction 
were the type of study, number of individuals, 





We searched four research libraries and found 1121 
relevant articles. 25 articles were found eligible for our 
study after removing duplicates, checking titles, 
abstracts, and full text. These 25 articles were finalized 
based on previously decided inclusion and exclusion 
criteria. The 25 selected articles include 12 case studies, 
10 retrospective studies, one randomized controlled 
trial, one non-randomized Controlled trial, and one 
prospective observational study. The column labeled 
as “COVID-19 Specific Treatment” contains the 
therapies that were used by the authors in their 
studies for targeting the COVID-19 virus specifically. 
Dosage and duration of use of these therapies are 
mentioned in the “Dosage and Duration” column. 
The column under the heading of, “Adjunct 
Treatment” includes drugs and therapies used for 
supportive treatment, superadded infections, and 
comorbidities. It also includes other drugs used for 
COVID-19 along with the COVID-19 specific 
treatment. The column under the heading of 
“Treatment Category” includes drugs and therapies 
which are classified as Anti-malarial, Anti-
inflammatory, Traditional Chinese Medicine, 
Corticosteroids, Anti-viral, Immunoglobulin therapy, 
Convalescent Plasma therapy, Mesenchymal Stem cell 
transplant therapy. 
Hydroxychloroquine showed remarkable results in all 
the above studies. Moreover, when a combination of 
hydroxychloroquine and azithromycin was used, even 
better results were observed. (Table 1&2) 
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Figure 1: Study selection design 
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No significant improvement was seen in patients 
receiving Lopinavir/ritonavir alone. However, when 
Interferon or Ribavarin was used along with 
Lopinavir/ritonavir a significant improvement was 
noticed in the above studies. Interferon and Ribavarin 
when used in combination without other antivirals 
also proved to be effective. Patients receiving 
Traditional Chinese medicine along with 
Lopinavir/ritonavir also showed significant 
improvements. Arbidol proved to be effective when 
used alone for patients of COVID-19. Oseltamivir 
when used alone did not prove to be effective. 
Intravenous Remdesivir also showed good results but 
requires testing on a large scale.(Tables 3-5) . 
All patients receiving Convalescent Plasma Therapy 
showed significant improvements and a decrease in 
viral load after infusion of plasma in above-mentioned 
studies (Table 6). All patients who received 
Immunoglobulin Therapy became afebrile and 
showed significant improvements (Table 7) 
Patients receiving Mesenchymal Stem Cell Therapy 
showed far better results than the control group 
receiving placebo. The patients receiving MSC became 
stable and were discharged from the hospital later on. 
114                                        Journal of Rawalpindi Medical College (JRMC); 2020; 24 COVID-19 Supplement-1: 108-117 
 
Traditional Chinese medicine also showed good 
results when used with western medicine but it 
should not be used as a single treatment modality for 




COVID-19 belongs to a family of beta coronavirus and 
has enveloped positive sense ribonucleic acid and 
attacks one main site for entry into cells. That site is an 
ACE2 receptor and the other thing responsible is a 
cellular serine protease TMPRSS2 protein required for 
HCOV-19 spike protein priming. Most of the body 
tissues which are abundant with ACE2 receptor (like 
myocardial tissue, alveolar type 2 cells in lungs and 
capillary endothelium, etc.) are severely affected by 
this virus. Another important way that it affects the 
body is by manipulating the body to release abundant 
inflammatory substances like interleukins and tumor 
necrosis factor to generate a cytokine storm which 
causes septic shock and multiple organ failure leading 
to death.13 Since there is no vaccine or specific drug for 
treatment, our best weapon against it would be drugs 
that prevent the virus to get attached to ACE2 
receptors or ACE2 inhibitors/blockers or drugs or 
treatments that prevent a cytokine response. Drugs 
that decrease viral load to stop viral shedding by an 
infected person are also the need of the hour. We will 
be discussing drugs that have undergone clinical trials 
and can be a potential treatment for COVID-19.  
Chloroquine phosphate and Hydroxychloroquine 
sulfate are very effective in decreasing the viral load of 
infected patients and alleviating their symptoms. They 
have been shown to have decreased the average 
duration of stay of infected people in hospitals and 
improved CT scan results and decreased viral load in 
patients in China. Hydroxychloroquine alters the pH 
of the cell membrane and prevents the fusion of the 
virus with host cells. It inhibits viral protein and 
nucleic acid replication and release of the virus. It also 
suppresses TNF alpha and IL-6.6 However, these 
results were observed with a specific dose of these 
drugs but were not observed below that dose. Since 
hydroxychloroquine is more effective than 
chloroquine and has fewer toxic effects and less 
interaction with other drugs that is why it is being 
preferred to chloroquine.3 Hydroxychloroquine has 
been used in combination with other drugs like 
azithromycin and antivirals so its effects, when used 
alone in patients, are still unknown and demand 
clinical studies[3,10]. Chloroquine and 
Hydroxychloroquine have been shown to prolong QTc 
interval which may cause arrhythmias.28 
Azithromycin has been used in combination with a 
couple of drugs for treating COVID-19 patients most 
commonly with Hydroxychloroquine and Antivirals 
and has shown good results. Viral load in patients 
receiving Hydroxychloroquine and Azithromycin 
combination showed a dramatic decrease when 
confirmed by PCR and Culture technique.3,10 Since 
Azithromycin has been commonly used by people for 
infections, there are very few chances of drug toxicity 
or intolerance to develop.10 Azithromycin has been 
shown to prevent respiratory tract infections when 
given to patients of viral infections.3 However, 
Azithromycin is contraindicated in pregnant females. 
29  
Lopinavir/ritonavir (LPV/r) had shown excellent 
results while treating SARS infection back in 2003. 
However, trials of lopinavir/ritonavir on COVID-19 
patients have not been satisfactory and suggest no 
satisfactory decrease in viral load.5,9 The patients 
receiving lopinavir/ritonavir had the same duration of 
stay in hospitals as the patients who received standard 
therapy. There were no significant improvements in 
CT scans of the lungs. LPV/r did not reduce the 
duration of viral shedding in patients.5,9 Moreover, the 
group receiving LPV/r had more gastrointestinal side 
effects like nausea, vomiting, and diarrhea as 
compared to the group receiving standard therapy.9 
However, patients with LPV/r therapy had a shorter 
stay in ICU as compared to the group receiving 
standard therapy. Hospital discharge was early in the 
LPV/r group with a difference of 1 day. In a clinical 
study percentage of patients showing improvements 
was higher in LPV/r group (45.5%) as compared to 
(30%) the group receiving standard therapy at the end 
of day 14.9 Umifenovir another antiviral has been seen 
to be effective in small clinical trials when used along 
with Ribavirin, Interferon-alpha, Oseltamivir, and 
Methylprednisolone.20,21,22 It was used for a patient 
who had undergone a renal transplant and was 
immune-compromised. It was seen that decreasing the 
amount of immunosuppressive drug and increasing 
methylprednisolone along with Umifenovir showed 
remarkable results and proved very effective. The 
patient was discharged on recovery.21 Umifenovir 
needs randomized large scale clinical trials for further 
assessment. Intravenous Remdesivir was advised to a 
patient who was previously receiving ibuprofen and 
acetaminophen for fever, guaifenesin for cough, 
vancomycin, and cefepime. The patient showed 
significant improvement after the intravenous 
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administration of Remdesivir.24 However, there are 
limited clinical trials of Remdesivir itself and further 
testing is required as it may be a potential treatment 
drug as well. Retrospective studies on Oseltamivir 
have shown that the use of this drug does not bear 
significant results.26 
Traditional Chinese medicine (TCM) has long been 
used in China for treating influenza and fever. Amidst 
COVID-19 outbreak traditional Chinese medicine was 
used in conjunction with western medicines like 
antivirals, antibiotics, oxygen therapy, interferon, and 
methylprednisolone.4,16,17 Patients receiving a 
combination of Chinese medicine and Western 
medicine showed significant improvement. In a 
clinical trial of 562 patients, both groups showed a 
lowering of fever but the group receiving a 
combination of Chinese and Western medicine 
showed a smoother decrease in body temperature to 
normal as compared to fluctuating fever in the group 
receiving only western medicine.28 The group 
receiving TCM also showed improvement of clinical 
symptoms like dyspnea, fatigue, cough, and malaise 
comparatively in shorter duration as compared to the 
group not receiving TCM. The consumption of 
corticosteroids was reduced in the group receiving 
TCM and chest radiographs showed reduced air-space 
shadowing of lungs. The death rate of severe patients 
in the group receiving TCM was 15.4% which is less as 
compared to the group receiving only western 
medicine (47.4%) [28]. TCM has been seen to show 
beneficial results when used with LPV/r for COVID-
19 [4,17]. Most of the herbal medicines fall into two 
categories which are drugs used to clear heat and 
dampness plus detoxification and the drugs that 
promote blood circulation and relieve blood stasis.30 
TCM functions to remove heat and toxicity from the 
lungs to relieve cough and boost immunity.17 
Moreover, TCM is cheap as compared to modern 
medicine and is cost-effective. However, it should be 
kept in mind that in neither of the clinical trials was 
TCM used alone as it effects slowly and should be 
used as a palliative treatment along with western 
medicine to increase efficacy. It should not be used as 
a single treatment modality.28 
Convalescent plasma therapy has been used before 
during the SARS outbreak.19 There has been limited 
work on convalescent plasma therapy for COVID-19 
but new trials have started to further assess this option 
due to remarkable results from studies done 
previously. The convalescent plasma of the donor 
contains antibodies against the organism which 
infected the donor. Antibodies from convalescent 
plasma may contribute to decrease viraemea and also 
to alleviate symptoms. In addition to viral neutralizing 
antibodies, the acceleration of infected cell clearance 
by antibodies has also been found in an in-vivo study 
of the HIV-1 virus.9,19 In the case of SARS-COV-2, it 
was seen that plasma from recovered COVID-19 
patient contains antibodies which can reduce the viral 
load in the host.8,19 Moreover, it has shown recovery of 
patients of COVID-19 who had progressed to ARDS. 
In a clinical trial of 5 critically ill COVID-19 patients, 
body temperature returned to normal within 3 days of 
transfusion. Patients who received convalescent 
plasma therapy showed negative PCR 12 days after 
plasma therapy. PaO2 also returned to normal on day 
12. These patients were also receiving other drugs 
(arbidol, lopinavir/ritonavir, oseltamivir, interferon-
alpha, ribavirin, and broad-spectrum antibiotics for 
other bacterial infections).19 In another clinical trial of 4 
patients, the RT-PCR test for COVID-19 came back 
negative in 3-22 days and two of the patients 
developed Anti SARS-CoV-2 IgG approximately 14 
days after plasma therapy. These patients were also 
receiving methylprednisolone, antivirals 
(lopinavir/ritonavir and interferon-alpha), and 
mechanical ventilation.8 Further trials need to be done 
on plasma therapy. Till now there have been no 
serious side effects due to plasma therapy. 
Mesenchymal cells have been seen to have the 
capability of modulating the deranged immune 
functions in the body by regulating the levels of 
cytokines in body and C reactive protein.13 There has 
been very little work done on this approach but the 
results achieved by recent clinical trials are 
satisfactory. In a clinical trial, 7 patients were injected 
MSC and 3 patients were included as a control 
group.13 The peripheral lymphocytes of the MSC 
injected group increased and overstimulated cytokine 
secreting cells disappeared in 3-6 days. The levels of 
tumor necrosis factor-alpha decreased and the level of 
interleukin-10 increased as compared to the control 
group. The patients in the MSC group were stable and 
3 of them were discharged whereas the control group 
deteriorated comparatively. The HCoV-19 nucleic acid 
test became negative 13 days after transfusion for all 
patients of the MSC group. Chest CT showed 
improvement of pneumonia 9 days after 
transplantation of MSC with less residual lung opacity 
on day 15 of transplantation. Thus, MSC IV 
suspensions prevent a cytokine storm and might be a 
therapy for severe COVID-19 patients.  
Passive immunization has long been used as a 
treatment and this approach has been studied for 
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COVID-19 by a series of clinical trials. IVIg is a blood 
product, obtained from the blood of healthy donors. It 
contains polyclonal Immunoglobulin G (IgG) that 
contains a large number of bioactive moieties. Several 
theories have been proposed to explain its 
immunomodulatory mechanism including Fc 
mediated and Fab mediated approaches. Considering 
its safety and efficacy in improving passive immunity 
and modulating immune inflammation, high-dose 
IVIg can be considered a treatment option at the early 
stage COVID-19 infection.15 In a clinical trial of 3 
patients, IV immunoglobulin was administered at 
25grams/day for 5 days.15 The patients became 
afebrile in the first 2 days after therapy started and all 
three of them discharged after a mean stay of 11 days 
in the hospital. Negative PCR testing of COVID-19 for 
all three patients came after 5 days of the start of 
immunoglobulin therapy. Chest CT scans also showed 
resolution of chest shadows. A high dose of IVIg (0.3-
0.5 gram/kg body weight) was used. Another clinical 
trial was done in which 2 patients received 
intravenous gammaglobulins.11 The patients also 
received methylprednisolone, moxifloxacin, arbidol 
hydrochloride, and oseltamivir for other possible 
infections by atypical bacteria or influenza virus but 
all test for these pathogens came back negative. The 
patient’s condition improved by gamma globulin 
usage and both were discharged after two weeks of 
treatment. Chest CT scans also showed resorption of 
previous lesions. Further assessment of this treatment 




So far, a small number of studies have been conducted 
on the treatment of COVID-19 patients and most of 
them were conducted on the Chinese population. 
More randomized -controlled -trials are needed to 
evaluate the effectiveness of different treatment 




Hydroxychloroquine and azithromycin were found 
effective in the treatment of COVID-19 patients.3,10 
LPV/r did not show satisfactory results in most of the 
COVID-19 patients.5,9 TCM was found to be effective 
when used along with Western medicine but cannot 
be used as a single modality for treatment.4,16,17 
Convalescent plasma therapy8,19, Intravenous 
Immunoglobulin11,15,  and Mesenchymal stem cells 
transplant13 were also found effective. In patients of 
organ transplant, withdrawal of immunosuppressive 
drugs, and the use of methylprednisolone along with 
antivirals had shown significantly good results.21 
Among all these therapeutic approaches we found 
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